PAG
NBIX icon

Private Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

Private Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,947
Closed -$710K – 222
2022
Q4 		$710K Buy
+5,947
New +$697K 0.16% 110

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Private Advisory Group's NBIX Position: Q1 2023 in Review

Private Advisory Group sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 5,947 shares — an estimated $710K sold.

Private Advisory Group first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $710K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Private Advisory Group reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Private Advisory Group sold 5,947 Neurocrine Biosciences shares in Q1 2023, an estimated $710K.
  • Private Advisory Group first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
  • Private Advisory Group's Neurocrine Biosciences position peaked at $710K in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Private Advisory Group's 13F filing for Q1 2023, filed 12 May 2023.